Servier has signed a deal with MiNA Therapeutics to develop novel small activating RNA (saRNA) therapies in neurological disorders.
The London-based biotech’s technology is based on the work of pioneering liver disease drug developer and surgeon Nagy Habib, who...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
